1. In Vivo
  2. >>Innovation

Healthcare In Crisis: A Vision Of More Human And Flexible Healthcare Experiences

Clinician, Patient Views Must Be Prioritized Ahead Of Health System Change

 
• By Ashley Yeo

Staff burnout, workforce attrition and patient backlogs are testing the resiliency of health systems. Crisis is not too big a word. Against this backdrop, GE HealthCare commissioned a major report, Reimagining Better Health 2023, which suggested ways of increasing trust and confidence in healthcare provider systems as they evolve.

Shutterstock

The COVID-19 pandemic and its aftermath put healthcare systems under unprecedented strain. Providers, doctors and nursing staff received universal acclaim for rising to the challenge of meeting demand for care.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Merck KGaA’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By Jo Shorthouse

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

More from In Vivo

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By Jo Shorthouse

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.